Healthcare Triangle, Inc.
For the period ended Mar 31, 2026. Filed May 14, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2026 · Filed May 14, 2026
HCTI$4.21-0.2%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Unaudited Condensed Consolidated Statements of Cash Flows
| Three Months Ended March 31, | |||||
|---|---|---|---|---|---|
| Note · 2026 · 2025 | |||||
| (In ‘000) | |||||
| Cash flows from operating activities | |||||
| Net loss | $(6,198) | $(1,700) | |||
| Adjustment to reconcile net loss to net cash provided by / (used in) operating activities | |||||
| Depreciation and amortization | 810 | 12 | |||
| Change in fair value | 2,435 | - | |||
| Common stock issued for services | - | 88 | |||
| Amortization of debt discount | - | 223 | |||
| Other income | - | (110) | |||
| Stock compensation expenses | - | 36 | |||
| Interest expenses | 89 | - | |||
| Interest expenses settled by equity | - | 316 | |||
| Bad debt expense | 125 | - | |||
| Changes in working capital: | |||||
| Increase in: | |||||
| Accounts receivable | (1,542) | (797) | |||
| Other current assets | (1,284) | (785) | |||
| Due from affiliates | - | (1,448) | |||
| Accounts payable | (280) | (820) | |||
| Other current liabilities | (1,019) | (572) | |||
| Net cash used in operating activities | (6,864) | (5,557) | |||
| Cash flows from investing activities | |||||
| Purchase of furniture and equipment | (22) | - | |||
| Acquisition of Teyame | 5 | (6,000) | - | ||
| Net cash used in investing activities | (6,022) | - | |||
| Cash flows from financing activities | |||||
| Net proceeds from short-term borrowing | 9 | 548 | 186 | ||
| Net proceeds from long-term debt | 9 | 269 | - | ||
| Payment of lease liability | 7 | (137) | - | ||
| Repayment of convertible note | - | (1,500) | |||
| Proceeds from equity issuance | 8,881 | 13,677 | |||
| Interest paid | (83) | - | |||
| Net cash provided by financing activities | 9,478 | 12,363 | |||
| Cumulative translation adjustment | 98 | - | |||
| Net increase / (decrease) in cash and cash equivalents | (3,310) | 6,806 | |||
| Cash and cash equivalents | |||||
| Cash and cash equivalents at the beginning of the year | 7,625 | 20 | |||
| Cash and cash equivalents at the end of the period | $4,315 | $6,826 | |||
| Supplementary disclosure of cash flows information | |||||
| Interest | $ | - | $413 | ||
| Conversion of debt to equity | 10,165 | 1,191 | |||
| Acquisition of Teyame (see note 5[B] for details) | $41,000 | $ | - | ||
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.